This looks like another interesting line of research and discovery.
http://www.koreabiomed.com/news/articleView.html?idxno=5611
According to the hospital, about 10 percent of the chronic myelogenous leukemia patients are resistant to the drug, and 20 percent of the patients develop resistance after receiving treatment with Gleevec.
The team, led by Professor Kim Dong-wook of the Department of Hematology at the hospital, found that a gene called Grancalcin regulates Gleevec resistance, identifying a molecular biologic mechanism that activates TRAF6-ULK1-dependent autophagy through a leukemia animal model.